Daiichi's Quizartinib Looks To Join Novartis' Rydapt In AML
Phase III results for Daiichi Sankyo's FLT3 targeting quizartinib are in, but it's unclear as yet how the data will affect a niche, targeted hematology/oncology market.
You may also be interested in...
Attempts to maximize the current commercial portfolio and prepare for upcoming pipeline launches spell more job losses at the US arm of major Japanese pharma Daiichi Sankyo.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Rydapt was approved by the US FDA for the one-third of patients with acute myeloid leukemia who test positive for a FLT3 mutation, which is associated with a poorer prognosis, and for advanced systemic mastocytosis.